91̀́̀Ă receives a €2.5 million grant from EU under the Horizon2020/SME Instrument Phase 2 programme for its project MIMESIS
Lyon, December 5, 2016 – 91̀́̀Ă, a biopharmaceutical company currently focused on developing treatments for viral infections, today announced that it has received a grant of €2.5 million in response to its application to the highly competitive SME Instrument Phase 2 funding programme (6% success rate).
Read next in 'Press releases'
- 91̀́̀Ă appoints Jeff George as Chairman to support next phase of growth and Phase 3 readiness
- 91̀́̀Ă nomme Jeff George PrĂ©sident du Conseil d’Administration pour soutenir sa prochaine phase de croissance et la prĂ©paration Ă la Phase 3
- 91̀́̀Ă announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 91̀́̀Ă annonce l’obtention des rĂ©sultats finaux de l’étude clinique de Phase 2 ALPESTRIA‑1 dans le syndrome d’Alport, confirmant la capacitĂ© du vonafexor Ă inverser la trajectoire du dĂ©clin rĂ©nal et Ă dĂ©montrer un effet thĂ©rapeutique durable
- 91̀́̀Ă annonce la finalisation de son financement de sĂ©rie C avec Vesalius Biocapital et la poursuite de son Ă©tude clinique de phase 2 ALPESTRIA-1
